Compare · EVGN vs NTR
EVGN vs NTR
Side-by-side comparison of Evogene Ltd (EVGN) and Nutrien Ltd. (NTR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVGN and NTR operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR is the larger of the two at $33.16B, about 5317.1x EVGN ($6.2M).
- Over the past year, EVGN is down 45.5% and NTR is up 15.1% - NTR leads by 60.6 points.
- NTR has been more active in the news (8 items in the past 4 weeks vs 6 for EVGN).
- NTR has more recent analyst coverage (25 ratings vs 4 for EVGN).
- Company
- Evogene Ltd
- Nutrien Ltd.
- Price
- $0.60+0.42%
- $68.81+0.45%
- Market cap
- $6.2M
- $33.16B
- 1M return
- -23.09%
- -9.25%
- 1Y return
- -45.45%
- +15.14%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 6
- 8
- Recent ratings
- 4
- 25
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest EVGN
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- SEC Form 424B3 filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- Evogene Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene to Present at the 24th Schrödinger European User Group Meeting
- Evogene Schedules First Quarter 2026 Financial Results Release
- SEC Form EFFECT filed by Evogene Ltd
- SEC Form 3 filed by new insider Ravzin Polina
- SEC Form EFFECT filed by Evogene Ltd
Latest NTR
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- SEC Form SUPPL filed by Nutrien Ltd.
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien Prices Offering of an Aggregate of US$1.0 Billion of 5-Year and 10-Year Senior Notes
- SEC Form FWP filed by Nutrien Ltd.
- SEC Form SUPPL filed by Nutrien Ltd.
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- Nutrien Announces Mark Thompson as a Speaker at the BMO Farm to Market Conference
- SEC Form 6-K filed by Nutrien Ltd.